retatrutide glp-1 receptor agonist Retatrutide, a GIP, and glucagon agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Triple G Agonists – Retatrutide.

Background: The evidence on berberine stimulating the secretion of GLP-1 in intestinal L cell has been studied

Find pharmacy-related safety alerts, drug recall and new generic drug announcements and other medication information for healthcare providers.

Learn about GLP-1 agonists, what they can help treat, and how they work to promote weight loss

Type 2 diabetes mellitus (T2DM) is a widespread metabolic disorder characterized by insulin resistance and pancreatic -cell dysfunction, posing a substantial global health challenge

Glucagon-like peptide-1 receptor agonists, namely GLP-1 receptor agonists, are a class of drugs for the treatment of type 2 diabetes.

The recently initiated large-sized FLOW trial investigating the effects of semaglutide on hard renal outcomes in patients with DKD will provide clarity whether GLP-1 receptor agonists may reduce the burden of DKD in addition to their other beneficial metabolic and cardiovascular effects.